Genitourinary Cancers | Emmanuel S Antonarakis, MD

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 1: Our one-on-one interview with Dr Antonarakis featuring emerging research and cases from his practice. Initial evaluation of prognostic indicators in hormone-sensitive prostate cancer (HSPC) versus castration-resistant prostate cancer (CRPC) (0:00) Effect of prostate-specific antigen (PSA) doubling time on time to metastasis and overall survival in nonmetastatic CRPC; improvement in metastasis-free survival with androgen receptor antagonist therapy (4:16) Perspective on the use of intermittent androgen deprivation therapy (ADT) for patients with nonmetastatic HSPC and rising PSA levels (12:35) Structural and mechanistic similarities and differences between available (apalutamide, enzalutamide) and investigational (darolutamide) androgen receptor antagonists (19:39) Initial results of the Phase III ARAMIS trial: Metastasis-free survival improvement and tolerability of darolutamide versus placebo for nonmetastatic CRPC (22:41) ARASENS: An ongoing Phase III trial evaluating darolutamide versus placebo in combination with standard ADT and docetaxel for patients with metastatic HSPC (25:38) Perspective on the new drug application and potential FDA approval of darolutamide for nonmetastatic CRPC (27:02) Spectrum and frequency of systemic and CNS-related side effects associated with apalutamide, enzalutamide and darolutamide (28:29) Updated analysis of progression-free survival with first subsequent therapy (PFS2) in the SPARTAN study of apalutamide for high-risk nonmetastatic CRPC (31:50) ARCHES: Design, efficacy and tolerability results from a Phase III trial of ADT with enzalutamide or placebo for metastatic HSPC (36:22) Selection and sequencing of therapy for patients with metastatic prostate cancer (42:01) Correlation between the presence of androgen receptor splice variant 7 (AR-V7) and outcomes with secondary hormonal therapy and chemotherapy in metastatic CRPC (45:58) Prevalence and detection of AR-V7 in patients with metastatic CRPC (50:48) Overview of BRCA1/2 and other DNA repair gene mutations that may confer sensitivity to PARP inhibition (54:32) Efficacy and FDA breakthrough therapy designations for olaparib and rucaparib for metastatic CRPC (58:49) GALAHAD: Preliminary results of a Phase II trial of niraparib for patients with metastatic CRPC and biallelic DNA repair gene defects (1:1:10) Response to PARP inhibitor therapy in patients with metastatic CRPC with BRCA1/2 versus ATM mutations (1:4:06) Activity of platinum-based chemotherapy in patients with metastatic CRPC and germline BRCA mutations (1:7:29) Clinical experience with PARP inhibitor-associated side effects in men with metastatic CRPC (1:12:35) Perspective on the negative results of the Phase III ERA 223 trial evaluating radium-223 dichloride in combination with abiraterone acetate for patients with chemotherapy-naïve metastatic CRPC and bone metastases (1:14:56) Appropriate use of radium-223 for the treatment of symptomatic metastatic CRPC (1:19:54) Biologic rationale for and ongoing investigation of lutetium-177-prostate-specific membrane antigen (PSMA)-617 for progressive PSMA-positive metastatic CRPC (1:23:03) KEYNOTE-199: Updated analysis of a Phase II trial of pembrolizumab monotherapy for patients with metastatic CRPC previously treated with docetaxel (1:27:39) Initial results of the Phase II CheckMate 650 trial of nivolumab with ipilimumab for metastatic CRPC (1:30:11) Prevalence of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) molecular phenotype and response to immune checkpoint blockade in patients with prostate cancer (1:35:02) Emerging data with olaparib in combination with anti-PD-1/PD-L1 checkpoint blockade for metastatic CRPC (1:37:38) Select publications